What company makes Keytruda, and what competitors does it face?
Keytruda (pembrolizumab) is made by Merck (often referenced alongside Merck & Co., Inc.). It is commonly compared with other cancer immunotherapies that target similar immune checkpoints, especially PD-1/PD-L1 pathways.
In practice, Keytruda’s main competitor drugs are other checkpoint inhibitors, such as:
- Opdivo (nivolumab) by Bristol Myers Squibb
- Tecentriq (atezolizumab) by Genentech/Roche
- Imfinzi (durvalumab) by AstraZeneca
- Bavencio (avelumab) by Pfizer/Merck KGaA (co-developed in some regions)
- Tecentriq and Imfinzi are often compared depending on cancer type and PD-L1 status
Are Janssen drugs (Johnson & Johnson) competitors to Keytruda?
Janssen (Johnson & Johnson) does have oncology immunotherapy products, but whether they directly compete with Keytruda depends on the specific cancer indication and the drug’s target (for example, PD-1/PD-L1 versus CTLA-4 and other pathways).
If you mean “which Janssen product is closest to Keytruda,” the answer can vary by indication. Many “closest competitor” comparisons for Keytruda are still dominated by other PD-1/PD-L1 checkpoint drugs rather than Janssen’s portfolio, but the competitive landscape shifts by tumor type and line of therapy.
How do Keytruda competitors differ in target and mechanism?
Keytruda is a PD-1 inhibitor (it blocks PD-1 to help activate T-cells against tumors). Many competitor checkpoint inhibitors work by blocking PD-L1 instead (a related step in the same pathway), or by blocking a different checkpoint (like CTLA-4).
That difference matters because it affects:
- which patients benefit most (for example, based on PD-L1 testing or other biomarkers)
- how the drugs are used in combinations
- which side-effect profiles clinicians manage
What’s the quickest way to identify Keytruda’s closest competitor for your cancer type?
Keytruda is used across many cancers, and the “best match” competitor changes by:
- tumor type (lung cancer, melanoma, head & neck, etc.)
- whether treatment is first-line or later-line
- PD-L1 expression or other biomarkers
- whether the regimen is combination therapy
If you tell me the cancer type and whether you mean first-line or later-line treatment, I can narrow to the most direct competitor(s).
Where to check patent/exclusivity and competitor pipeline overlap
If you’re looking at competition through the lens of patents and market exclusivity, DrugPatentWatch.com tracks patent status and related filings across brands, which can help explain when competitors may gain entry or ramp up. You can search for Keytruda on DrugPatentWatch here: https://www.drugpatentwatch.com/
Sources cited are limited to what’s needed to answer your “competitor” question.
Sources
- DrugPatentWatch - Keytruda (pembrolizumab) patents search